Updates in the Treatment of Mantle Cell Lymphoma

This article discusses the current treatment landscape and therapeutic strategies for mantle cell lymphoma, the role of Bruton tyrosine kinase inhibitor therapies in MCL, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

Related Videos
Jorge E. Cortes, MD
Bradley W. Christensen, MD
Expert on AML
Expert on AML
Akash Mukherjee, MD
Zachary Epstein-Peterson, MD
Andre H. Goy, MD
Craig Sauter, MD
Experts on AML
Expert on AML
Related Content

Acalabrutinib Receives Approval in China for Relapsed/Refractory Mantle Cell Lymphoma

March 23rd 2023

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023

Real-World Analysis Evaluates Inpatient Vs Outpatient CAR T-Cell Therapy Administration in MCL and FL

March 21st 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

ASCT Following First Complete Remission Does Not Improve Real-World Survival in Mantle Cell Lymphoma

March 19th 2023

Triplets and Targeted Therapies May Strengthen the R/R AML Armamentarium

March 18th 2023

Acalabrutinib Receives Approval in China for Relapsed/Refractory Mantle Cell Lymphoma

March 23rd 2023

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023

Real-World Analysis Evaluates Inpatient Vs Outpatient CAR T-Cell Therapy Administration in MCL and FL

March 21st 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

ASCT Following First Complete Remission Does Not Improve Real-World Survival in Mantle Cell Lymphoma

March 19th 2023

Triplets and Targeted Therapies May Strengthen the R/R AML Armamentarium

March 18th 2023

Acalabrutinib Receives Approval in China for Relapsed/Refractory Mantle Cell Lymphoma

March 23rd 2023

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023

Real-World Analysis Evaluates Inpatient Vs Outpatient CAR T-Cell Therapy Administration in MCL and FL

March 21st 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

ASCT Following First Complete Remission Does Not Improve Real-World Survival in Mantle Cell Lymphoma

March 19th 2023

Triplets and Targeted Therapies May Strengthen the R/R AML Armamentarium

March 18th 2023